Kamala ThriemerBenedikt LeyAlbino BobogareLek DysoleyMohammad Shafiul AlamAyodhia P. PasaribuJetsumon SattabongkotElodie JambertGonzalo J. DomingoRobert CommonsSarah AuburnJutta MarfurtAngela DevineMohammad M. AktaruzzamanNayeem SohelRinzin NamgayTobgyel DrukpaSurender Nath SharmaElvieda SarawatiIriani SamadMinerva TheodoraSimone NambanyaSonesay OunekhamRose Nanti Binti MudinGarib Da ThakurLeo Sora MakitaRaffy DeraySang Eun LeeLeonard BoazManjula N. DanansuriyaSantha D. MudiyanselageNipon ChinanonwaitSuravadee KitchakarnJohnny NausienEsau NaketThang Ngo DucHa Do ManhYoung S. HongQin ChengJack S. RichardsRita KusriastutiAri SatyagrahaRintis NoviyantiXavier C. DingWasif Ali KhanChing Swe PhruZhu GuodingGao QiAkira KanekoOlivo MiottoWang NguitragoolWanlapa RoobsoongKatherine BattleRosalind E. HowesArantxa Roca-FeltrerStephan DuparcIpsita Pal BhowmickEnny KenangalemJo Anne BibitAlyssa BarryDavid SintasathRabindra AbeyasingheCarol H. SibleyJames McCarthyLorenz Von SeidleinJ. Kevin BairdRic N. PriceMenzies School of Health ResearchNational Vector Borne Disease Control ProgrammeNational Center for Parasitology, Entomology and Malaria ControlNational Institute of Public HealthInternational Centre for Diarrheal Diseases and ResearchUniversitas Sumatera UtaraMahidol UniversityMedicines for Malaria Venture (MMV)PATHMahidol-Oxford Tropical Medicine Research UnitNuffield Department of Clinical MedicineMinistry of Health and Family WelfareMinistry of Health in BhutanMinistry of Health and Family WelfareNational Malaria Control ProgramNational Center for Entomology Parasitology and Malaria ControlKementerian Kesihatan MalaysiaMinister for Health and Population NepalNational Malaria Control ProgrammeDepartment of Health ManilaKorea Centers for Disease Control & PreventionMinistry of Health ColomboThailand Ministry of Public HealthNational Malaria Control ProgrammeNational Institute of Malaria, Parasitology, and Entomology (NIMPE)Access Bio IncAustralian Army Malaria InstituteBurnet InstituteMinistry of Health, Republic of IndonesiaIndonesian Medical AssociationEijkman Institute of Molecular BiologyFINDJiangsu Institute of Parasitic DiseasesKarolinska InstitutetOsaka City UniversityWellcome Trust Centre for Human GeneticsWellcome Trust Sanger InstituteMalaria ConsortiumIndian Council of Medical ResearchYayasan Pengembangan Kesehatan dan Masyarakat Papua TimikaGokilaWalter and Eliza Hall Institute of Medical ResearchUniversity of MelbourneUnited States Agency for International DevelopmentOrganisation Mondiale de la SantéWWARNUniversity of Washington, SeattleQIMR Berghofer Medical Research InstituteEijkman-Oxford Clinical Research Unit2018-12-212019-03-142018-12-212019-03-142017-04-05Malaria Journal. Vol.16, No.1 (2017)147528752-s2.0-85016978562https://repository.li.mahidol.ac.th/handle/20.500.14594/42843© 2017 The Author(s). The delivery of safe and effective radical cure for Plasmodium vivax is one of the greatest challenges for achieving malaria elimination from the Asia-Pacific by 2030. During the annual meeting of the Asia Pacific Malaria Elimination Network Vivax Working Group in October 2016, a round table discussion was held to discuss the programmatic issues hindering the widespread use of primaquine (PQ) radical cure. Participants included 73 representatives from 16 partner countries and 33 institutional partners and other research institutes. In this meeting report, the key discussion points are presented and grouped into five themes: (i) current barriers for glucose-6-phosphate deficiency (G6PD) testing prior to PQ radical cure, (ii) necessary properties of G6PD tests for wide scale deployment, (iii) the promotion of G6PD testing, (iv) improving adherence to PQ regimens and (v) the challenges for future tafenoquine (TQ) roll out. Robust point of care (PoC) G6PD tests are needed, which are suitable and cost-effective for clinical settings with limited infrastructure. An affordable and competitive test price is needed, accompanied by sustainable funding for the product with appropriate training of healthcare staff, and robust quality control and assurance processes. In the absence of quantitative PoC G6PD tests, G6PD status can be gauged with qualitative diagnostics, however none of the available tests is currently sensitive enough to guide TQ treatment. TQ introduction will require overcoming additional challenges including the management of severely and intermediately G6PD deficient individuals. Robust strategies are needed to ensure that effective treatment practices can be deployed widely, and these should ensure that the caveats are outweighed by the benefits of radical cure for both the patients and the community. Widespread access to quality controlled G6PD testing will be critical.Mahidol UniversityImmunology and MicrobiologyArticleSCOPUS10.1186/s12936-017-1784-1